New concepts in the management of adverse drug reactions

Authors: Bahna, Sami L.1; Khalili, Barzin1

Source: Allergy and Asthma Proceedings, Volume 28, Number 5, September-October 2007 , pp. 517-524(8)

Publisher: OceanSide Publications, Inc

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Our understanding of drug reactions and their management has changed markedly in recent years with the development of several new concepts. Epidermal cell death seen in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) may result from Fas-Fas ligand-mediated apoptosis. Intravenous immunoglobulin (IVIG) contains anti-Fas antibodies that can abrogate apoptosis. Most studies on IVIG in SJS and TEN reported improvement in arresting disease progression and reduction in time to healing. Furthermore, several studies have dispelled the myth of sulfonamide cross-reactivity. Immune-mediated reactions against antibacterial sulfonamides are directed against two unique side chains that non-antibacterial sulfonamides do not contain. Certain patients seem to have a genetic predisposition for “multiple drug sensitivities.” Hence, they may react to several drugs that are not necessarily cross-reacting. Also, multiple studies have shown that IgE-mediated nonsteroidal anti-inflammatory drugs (NSAIDs) cross-reactivity is uncommon. Rather, it is cyclooxygenase (COX) 1 inhibition that results in pseudoallergic reactions to multiple NSAIDs. Several studies have indicated that selective COX-2 inhibitors can be safely administered in patients with aspirin-exacerbated respiratory disease and NSAID-induced cutaneous reactions, although their use has been curtailed by their cardiovascular side effects. Biological agents, such as infliximab, are being increasingly used for a variety of diseases and have caused adverse reactions in some patients. Studies differ as to whether concomitant immunosuppressive use with infliximab affects the development of drug-specific antibodies and infusion reactions. Successful desensitization protocols have been developed for reactions to some of these agents.

Keywords: Drug allergy; drug cross-reactivity; drug hypersensitivity; immunoglobulin therapy; infliximab; NSAIDs; pancreatic enzyme; Stevens-Johnson syndrome; sulfonamides; toxic epidermal necrolysis

Document Type: Review article

DOI: 10.2500/aap2007.28.3030

Affiliations: 1: From the Allergy and Immunology Section, Louisiana State University Health Sciences Center, Shreveport, Louisiana

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$39.50 plus tax      Refund Policy

 

OR

Or sign up for a free trial

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A